COMPOSITIONS AND METHODS FOR mRNA DELIVERY
US-2015366997-A1 · Dec 24, 2015 · US
Using nucleic acids encoding NAP-2 polypeptides to improve cardiac function
US11413330B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11413330-B2 |
| Application number | US-202016891344-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 3, 2020 |
| Priority date | Sep 3, 2013 |
| Publication date | Aug 16, 2022 |
| Grant date | Aug 16, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk for experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCT) for ST-elevation myocardial infarction (STEMI) are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for modulating immune system activity in heart tissue following cardiac injury, the method comprising: administering a composition comprising a nucleic acid encoding a neutrophil-activating protein-2 (NAP-2) polypeptide to heart tissue of a mammal, thereby modulating immune system activity in the heart tissue. 2. The method of claim 1 , wherein the mammal is a human. 3. The method of claim 1 , wherein the method comprises administering the composition during a percutaneous coronary intervention. 4. The method of claim 1 , wherein the cardiac injury comprises ischemic reperfusion injury.
Assignees
Inventors
Classifications
Transforming growth factor [TGF] · CPC title
Immunomodulators · CPC title
characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title
from muscle, cartilage or connective tissue · CPC title
- A61K38/195Primary
Chemokines, e.g. RANTES · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11413330B2 cover?
- This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk for experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCT) for…
- Who is the assignee on this patent?
- Mayo Found Medical Education & Res
- What technology area does this patent fall under?
- Primary CPC classification A61K38/195. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).